Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Study ID: NCT05899608
Start Date: 2023-10-26
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1080

Intervention / Treatment

Ivonescimab Injection

Pembrolizumab Injection

Sponsor

Summit Therapeutics

Source: clinicaltrials.gov

Share:
Add to list

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

Study ID: NCT03527108
Start Date: 2020-10-08
End Date: 2027-04
Study Type

Interventional

Study Phase

Phase2

No. of Participants

39

Intervention / Treatment

Nivolumab

Ramsirumb

Sponsor

Fox Chase Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Integrated Actionable Aging Assessment for Cancer Patients Pilot

Study ID: NCT05871008
Start Date: 2024-03-01
End Date: 2026-12
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

35

Intervention / Treatment

Assessment tool IA3-CP with SDoH

Assessment tool IA3-CP without SDoH

Sponsor

University of Colorado, Denver

Source: clinicaltrials.gov

Share:
Add to list

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Study ID: NCT06890923
Start Date: 2025-03-04
End Date: 2026-08-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

55

Intervention / Treatment

Foralumab TZLS-401 100 µg

Sponsor

Tiziana Life Sciences LTD

Source: clinicaltrials.gov

Share:
Add to list

Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung Cancer

Study ID: NCT06743308
Start Date: 2024-12-16
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Best Practice

Administration questionnaire

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Study ID: NCT04472338
Start Date: 2020-05-21
End Date: 2030-08-31
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

450

Intervention / Treatment

Biospecimen Collection

Laboratory Biomarker Analysis

Quality-of-Life Assessment

Administration questionnaire

Sponsor

University of Washington

Source: clinicaltrials.gov

Share:
Add to list

Neoadjuvant Breast Cancer Time Restricted Eating

Study ID: NCT05327608
Start Date: 2022-07-28
End Date: 2027-05-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

55

Intervention / Treatment

Time Restricted Eating

Sponsor

Thomas Jefferson University

Source: clinicaltrials.gov

Share:
Add to list

Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer

Study ID: NCT06246955
Start Date: 2024-01-08
End Date: 2027-12-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

200

Intervention / Treatment

Behavioral Intervention: Group Therapy Session

Survey Administration

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study ID: NCT06859008
Start Date: 2026-02-07
End Date: 2029-01-31
Study Type

Interventional

Study Phase

Phase1

No. of Participants

37

Intervention / Treatment

Biopsy

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Computed Tomography

Magnetic Resonance Imaging

Administration questionnaire

Sonrotoclax

Zanubrutinib

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Study ID: NCT04614103
Start Date: 2021-05-07
End Date: 2031-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

170

Intervention / Treatment

LN-145

LN-145

Sponsor

Iovance Biotherapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list